A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children age 7 years through 18 years To assess the efficacy (the incidence of laboratory-confirmed influenza infection caused by any community-acquired wild-type strains matched to the vaccine) of MEDI3250 compared to placebo. To asses...

• Country None
• organs None
• Specialty None

A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children age 2 years through 6 years To assess the safety and tolerability of MEDI3250.

• Country None
• organs None
• Specialty None